BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND PTCH1, RP11-435O5_3, Q13635, PTCH, 5727, HPE7, FLJ26746, NBCCS, BCNS, PTC1, ENSG00000185920, FLJ42602 AND Prognosis
31 results:

  • 1. Genetic insights into thymic carcinomas and thymic neuroendocrine neoplasms denote prognosis signatures and pathways.
    Wang S; Gu Z; Zhu L; Han Y; Yu H; Fang W; Han B
    Chin Med J (Engl); 2023 Nov; 136(22):2712-2721. PubMed ID: 37749819
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
    Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
    Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. GLI-1 polymorphisms of Hedgehog pathway as novel risk and prognostic biomarkers in melanoma patients.
    Dunjic M; Lukic N; Djordjevic B; Uzelac B; Ostojic N; Supic G
    Melanoma Res; 2022 Feb; 32(1):11-17. PubMed ID: 34939981
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator.
    Korshunov A; Okonechnikov K; Stichel D; Ryzhova M; Schrimpf D; Sahm F; Sievers P; Absalyamova O; Zheludkova O; Golanov A; Jones DTW; Pfister SM; von Deimling A; Kool M
    Neuro Oncol; 2021 Sep; 23(9):1576-1585. PubMed ID: 33589929
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target.
    Yang C; Yong L; Liang C; Li Y; Ma Y; Wei F; Jiang L; Zhou H; He G; Pan X; Hai B; Wu J; Xu Y; Liu Z; Liu X
    Oncogene; 2020 Jun; 39(24):4711-4727. PubMed ID: 32404987
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker.
    Korshunov A; Okonechnikov K; Sahm F; Ryzhova M; Stichel D; Schrimpf D; Ghasemi DR; Pajtler KW; Antonelli M; Donofrio V; Mastronuzzi A; Rossi S; Camassei FD; Buccoliero AM; Haberler C; Slavc I; Dahiya S; Casalini B; Sievers P; Meyer J; Kumirova E; Zheludkova O; Golanov A; Jones DTW; Pfister SM; Kool M; von Deimling A
    Acta Neuropathol; 2020 Mar; 139(3):583-596. PubMed ID: 31781912
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
    Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
    Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas.
    Menyhárt O; Győrffy B
    Ann Clin Transl Neurol; 2019 May; 6(5):990-1005. PubMed ID: 31139698
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. MiR-9 promotes tumorigenesis and angiogenesis and is activated by MYC and OCT4 in human glioma.
    Chen X; Yang F; Zhang T; Wang W; Xi W; Li Y; Zhang D; Huo Y; Zhang J; Yang A; Wang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):99. PubMed ID: 30795814
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.
    Cambruzzi E
    Childs Nerv Syst; 2018 May; 34(5):809-815. PubMed ID: 29582169
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Molecular characterization of medulloblastomas with extensive nodularity (MBEN).
    Korshunov A; Sahm F; Stichel D; Schrimpf D; Ryzhova M; Zheludkova O; Golanov A; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
    Acta Neuropathol; 2018 Aug; 136(2):303-313. PubMed ID: 29569031
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis.
    Guerrini-Rousseau L; Dufour C; Varlet P; Masliah-Planchon J; Bourdeaut F; Guillaud-Bataille M; Abbas R; Bertozzi AI; Fouyssac F; Huybrechts S; Puget S; Bressac-De Paillerets B; Caron O; Sevenet N; Dimaria M; Villebasse S; Delattre O; Valteau-Couanet D; Grill J; Brugières L
    Neuro Oncol; 2018 Jul; 20(8):1122-1132. PubMed ID: 29186568
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Association of expression of the hedgehog signal with Merkel cell polyomavirus infection and prognosis of Merkel cell carcinoma.
    Kuromi T; Matsushita M; Iwasaki T; Nonaka D; Kuwamoto S; Nagata K; Kato M; Akizuki G; Kitamura Y; Hayashi K
    Hum Pathol; 2017 Nov; 69():8-14. PubMed ID: 28551328
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. ARID1B alterations identify aggressive tumors in neuroblastoma.
    Lee SH; Kim JS; Zheng S; Huse JT; Bae JS; Lee JW; Yoo KH; Koo HH; Kyung S; Park WY; Sung KW
    Oncotarget; 2017 Jul; 8(28):45943-45950. PubMed ID: 28521285
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Negative prognostic effect of low nuclear GLI1 expression in glioblastomas.
    Kim Y; Do IG; Hong M; Suh YL
    J Neurooncol; 2017 May; 133(1):69-76. PubMed ID: 28417299
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy.
    Paret C; Theruvath J; Russo A; Kron B; El Malki K; Lehmann N; Wingerter A; Neu MA; Gerhold-Ay A; Wagner W; Sommer C; Pietsch T; Seidmann L; Faber J
    Oncotarget; 2016 Dec; 7(50):83378-83391. PubMed ID: 27825128
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma.
    Andrade AF; Borges KS; Suazo VK; Geron L; Corrêa CA; Castro-Gamero AM; de Vasconcelos EJ; de Oliveira RS; Neder L; Yunes JA; Dos Santos Aguiar S; Scrideli CA; Tone LG
    Invest New Drugs; 2017 Feb; 35(1):26-36. PubMed ID: 27785591
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial.
    Clifford SC; Lannering B; Schwalbe EC; Hicks D; O'Toole K; Nicholson SL; Goschzik T; Zur Mühlen A; Figarella-Branger D; Doz F; Rutkowski S; Gustafsson G; Pietsch T;
    Oncotarget; 2015 Nov; 6(36):38827-39. PubMed ID: 26420814
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. "ptch"-ing it together: a basal cell nevus syndrome review.
    Lam C; Ou JC; Billingsley EM
    Dermatol Surg; 2013 Nov; 39(11):1557-72. PubMed ID: 23725561
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Canonical TGF-β pathway activity is a predictor of SHH-driven medulloblastoma survival and delineates putative precursors in cerebellar development.
    Aref D; Moffatt CJ; Agnihotri S; Ramaswamy V; Dubuc AM; Northcott PA; Taylor MD; Perry A; Olson JM; Eberhart CG; Croul SE
    Brain Pathol; 2013 Mar; 23(2):178-91. PubMed ID: 22966790
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.